Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2389-2396

  Koutros, Stella ^a   Schumacher, Fredrick R ^b   Hayes, Richard B ^c   Ma, Jing ^d   Huang, Wen Yi ^a   Albanes, Demetrius ^a   Canzian, Federico ^f   Chanock, Stephen J ^a   Crawford, E David ^g   Diver, W Ryan ^h   Feigelson, Heather Spencer ^h,i   Giovanucci, Edward ^e   Haiman, Christopher A ^b   Henderson, Brian E ^b   Hunter, David J ⁱ   Kaaks, Rudolf ^f   Kolonel, Laurence N ^j   Kraft, Peter ^e   Le Marchand, Loïc ^j   Riboli, Elio ^k   Siddiq, Afshan ^k   Stampfer, Mier J ^d,e   Stram, Daniel O ^b   Thomas, Gilles ^a   Travis, Ruth C ^l   Thun, Michael J ^h   Yeager, Meredith ^a   Berndt, Sonja I ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY OF COLORADO   (United States)

^h AMERICAN CANCER SOCIETY   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C;

ADULT; AGED; ALLELE; ARTICLE; CANCER CENTER; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PHOSPHATIDYLINOSITOL 3 KINASE GENE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 77950226852     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3575     Document Type: Article

References (45)

1. Foster FM, Traer CJ, Abraham SM, Fry MJ. The phosphoinositide (PI) 3-kinase family. J Cell Sci 2003;116:3037-3040
2. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507.
3. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-723
4. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
5. Allen NE, Key TJ, Appleby PN, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007;16:1121-1127
6. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566
7. Cheng I, DeLellis HK, Haiman CA, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 2007;92:3660-3666
8. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-262
9. Boormans JL, Hermans KG, van Leenders GJ, Trapman J, Verhagen PC. An activating mutation in AKT1 in human prostate cancer. Int J Cancer 2008;123:2725-2726
10. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947
11. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
12. Quaye L, Song H, Ramus SJ, et al. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer 2009;100:993-1001.
13. Li L, Plummer SJ, Thompson CL, Tucker TC, Casey G. Association between phosphatidylinositol 3-kinase regulatory subunit p85α Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 2008;14:633-637
14. Paradis AE, Kantoff PW, Giovannucci E, Stampfer MJ, Ma J. Association between the Met326Ile polymorphism of the p85α regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2003;12:172-173
15. Haiman CA, Stram DO, Cheng I, et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1021-1025
16. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR. The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 2009;417:411-421
17. Kang D, Lee KM, Park SK, et al. Lack of association of transforming growth factor-β1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial. Cancer Epidemiol Biomarkers Prev 2007;16:1303-1305
18. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5:977-985
19. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-1106
20. Weiss JM, Huang WY, Rinaldi S, et al. IGF-1 and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2007;121:2267-2273
21. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-3994
22. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74:106-120
23. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu Rev Genomics Hum Genet 2009;10:387-406.
24. de Bakker PI, Burtt NP, Graham RR, et al. Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 2006;38:1298-1303
25. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12:921-927
26. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434
27. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003;55:56-65.
28. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 2008;32:361-369
29. Katso RM, Pardo OE, Palamidessi A, et al. Phosphoinositide 3-Kinase C2β regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 2006;17:3729-3744
30. Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, Falasca M. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 2005;169:789-799
31. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998;333: 471-490
32. Brown RA, Shepherd PR. Growth factor regulation of the novel class II phosphoinositide 3-kinases. Biochem Soc Trans 2001;29:535-537
33. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006;58: 124-145
34. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009; 124:2416-2429
35. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638
36. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675-684
37. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007;16:63-69
38. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003.
39. Jeyaraj S, O'Brien DM, Chandler DS. MDM2 and MDM4 splicing: an integral part of the cancer spliceome. Front Biosci 2009;14:2647-2656
40. Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. Nat Genet 2007;39:1202-1207
41. Gronberg H, Isaacs SD, Smith JR, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997;278:1251-1255
42. Klein EA, Kupelian PA, Witte JS. Does a family history of prostate cancer result in more aggressive disease? Prostate Cancer Prostatic Dis 1998;1:297-300.
43. Rodriguez C, Calle EE, Miracle-McMahill HL, et al. Family history and risk of fatal prostate cancer. Epidemiology 1997;8:653-657
44. Fitzgerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res 2009;15:3231-3237
45. Schaid DJ, McDonnell SK, Zarfas KE, et al. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006;120: 471-485